In a nutshell
This project will investigate the role of proteins called
phosphatases in regulation of Androgen Receptor function. The
aim of this work is to identify whether phosphatases are potential
therapeutic targets for prostate cancer treatment.
Why we funded it
The androgen receptor (AR) is a protein that is present in cells
in the prostate, especially cancer cells. AR activation is closely
linked to prostate cancer growth. The AR gets activated when
hormones called androgens, which promote cell growth (for example
testosterone), bind to it.
Hormone therapy can initially block AR activation by preventing
androgens from reaching the AR. However, over time the cancer cells
often find a way to activate the AR even without androgen binding.
The resultant resistant form of prostate cancer is very difficult
to treat, so new treatment options are needed. The proposed study
investigates a group of proteins called phosphatases, which can
regulate AR activation. If these proteins can also be shown to
regulate AR function, they may eventually provide new drug targets
for the treatment of advanced prostate cancer.
Read a more detailed summary of this project here.